Skip to main content

Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate

Osteoporosis International volume 14, pages 9–12 (2003)Cite this article

Abstract

Strontium ranelate (SR) is currently being developed for the treatment of osteoporosis. Pharmacologic studies in animal models have shown that its efficacy on bone mass is based on its original mode of action on bone formation and bone resorption. In normal mice, SR increased bone formation and vertebral bone mass. In normal rats, SR increased bone mass and the mechanical properties of vertebral, humeral and femoral bones, associated with increased femoral shaft diameter. Vertebral bone mineral density and bone strength were also increased by SR, whereas stiffness was not altered, underlining that the improvement in bone strength occurs without inducing defective bone mineralization. In normal adult monkey alveolar bone, SR decreased bone resorption and increased bone. In ovariectomized (OVX) rats, SR limited the reduction in bone mineral content and the decrease in trabecular bone volume induced by estrogen deficiency, by inhibiting bone resorption while maintaining bone formation. Curative treatment with SR also partially restored bone mass in OVX rats. In the model of hind limb immobilization in rats, SR reduced bone resorption and partially limited long bone loss, as assessed by bone mineral content, bone volume, and histomorphometric and biochemical indices of bone resorption. The unique mode of action of SR on bone formation and resorption is also supported by in vitro studies. In calvaria culture systems and osteoblastic cell cultures, SR enhanced the replication of preosteoblastic cells and consequently increased collagen synthesis. Moreover, SR inhibited the bone-resorbing activity of isolated mouse osteoclasts and devreased osteoclast differentiation markers in chicken bone marrow cultures. Altogether, these pharmacologic results suggest that SR optimizes bone metabolism by decreasing bone resorption and promoting bone formation, which may be of potential value in the treatment of osteoporosis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1.

References

  1. Marie PJ. Effects of strontium on bone formation and bone cells. In: Neve J, Chappuis P, Lamand M, editors. Therapeutic uses of traces elements. New York: Plenum Press, 1996:277–82.

  2. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121–9.

    CAS  PubMed  Google Scholar 

  3. Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002;51:906–11.

  4. Arlot ME, Roux JP, Boivin G, Perrat B, Tsouderos Y, Deloffre P, Meunier PJ. Effects of a strontium salt (S12911) on both tibial metaphysis and epiphysis in normal growing rats. J Bone Miner Res 1995;10(Suppl 1):356.

  5. Ammann P, Robin B, Bonjour JP, Tupinon-Mathieu I, Meyer JM, Rizzoli R. Long-term exposure to strontium ranelate dose-dependently increases bone strength in intact female rats [abstract]. Bone 2001;5(Suppl):S220.

  6. Ammann P, Rizzoli R, Deloffre P, Tsouderos Y, Meyer JM, Bonjour JP. Long-term administration of a high dose of the strontium salt S12911 has no toxic effect on bone biomechanics in female rats and may improve bone strength of the midshaft humerus. J Bone Miner Res 1995;10(Suppl 1):358.

  7. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001;29:176–9.

    Article  CAS  PubMed  Google Scholar 

  8. Shen V, Liu C, Marque V, Dupin-Roger I, Bazot D, Tupinon-Mathieu I. Histomorphometric evaluation of the tibiofibular junction after a long-term oral administration of S12911 in female rats. Bone Miner Res 2001;17(Suppl 1):375

  9. Ammann P, Robin B, Bonjour JP, Tupinon-Mathieu I, Meyer JM, Rizzoli R. Long-term exposure to strontium ranelate dose-dependently increases bone strength in intact female rats [abstract]. Bone 2001;5(Suppl);S220.

  10. Marie PJ, Hott M, Modrowski D, de Pollak C, Guillemain J, Deloffre P, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8:607–15.

    CAS  PubMed  Google Scholar 

  11. Arlot ME, Braillon P, Roux JP, Deloffre P, Tsouderos Y, Meunier PJ. A new agent containing strontium (S12911) has a protective effect on bone loss in ovariectomized rats [abstract]. Bone 1992;13:A1.

    PubMed  Google Scholar 

  12. Marie PJ, Hott M, Modrowski D, Chappuis P, Guillemain J, Deloffre P, Tsouderos Y. S12911, a new agent containing strontium, inhibits bone loss due to immobilization in rats. J Bone Miner Res 1995;10(Suppl 1):165.

  13. Su Y, Bonnet J, Deloffre P, Tsouderos Y, Baron R. The strontium salt S12911 inhibits bone resorption in mouse calvaria and isolated rat osteoclast cultures. Bone Miner 1992;17(Suppl 1):188.

  14. Takahashi N, Sasaki T, Tsouderos Y, Suda T. Strontium ranelate inhibits osteoclastic bone resorption in vitro. J Bone Miner Res (submitted).

  15. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002;450:11–7.

  16. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996;18:517–23.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. INSERM U349 affiliated CNRS, Lariboisière Hospital, 2 rue Ambroise Pare, 75475 , Paris cedex 10, France

    P. J. Marie

Authors
  1. P. J. Marie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. J. Marie.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Marie, P.J. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. Osteoporos Int 14, 9–12 (2003). https://doi.org/10.1007/s00198-002-1344-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-002-1344-5

Keywords

  • Bone resorption
  • Bone formation
  • Bone mass
  • Strontium ranelate